Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H2 2017 - Research and Markets

Research and Markets
Posted on: 24 Nov 17

The "Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes.

The latest report Tyrosine Protein Kinase Receptor UFO - Pipeline Review, H2 2017, outlays comprehensive information on the Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Key Topics Covered:

  1. Introduction
  2. Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Overview
  3. Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Therapeutics Assessment
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Companies Involved in Therapeutics Development
  • Astellas Pharma Inc
  • BerGenBio ASA
  • Betta Pharmaceuticals Co Ltd
  • Celldex Therapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Exelixis Inc
  • Ignyta Inc
  • Les Laboratoires Servier SAS
  • Mirati Therapeutics Inc
  • Ono Pharmaceutical Co Ltd
  • Oribase Pharma
  • Qurient Co Ltd
  • Rigel Pharmaceuticals Inc
  • SignalChem Lifesciences Corp
  • Takeda Pharmaceutical Co Ltd
  • Tolero Pharmaceuticals Inc

For more information about this report visit https://www.researchandmarkets.com/research/f6mkfx/tyrosine_protein

View source version on businesswire.com: http://www.businesswire.com/news/home/20171124005172/en/

Business Wire
www.businesswire.com

Last updated on: 24/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.